{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:09:43Z","timestamp":1780434583340,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijid.2024.107314","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:52:12Z","timestamp":1732603932000},"page":"107314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Outcomes of adjunctive eravacycline for severe and fulminant Clostridioides difficile infection"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9787-358X","authenticated-orcid":false,"given":"Christen J.","family":"Arena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-2204","authenticated-orcid":false,"given":"Rachel M.","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":false,"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.107314_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciae087","article-title":"Reduced vancomycin Susceptibility in Clostridioides difficile Is Associated with Lower Rates of Initial Cure and Sustained Clinical Response","volume":"79","author":"Eubank","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107314_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: a clinical microbiological study","volume":"37","author":"Tsai","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijid.2024.107314_bib0003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archsurg.2009.51","article-title":"Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality","volume":"144","author":"Sailhamer","year":"2009","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijid.2024.107314_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/BF02056938","article-title":"Clostridium difficile colitis in the critically ill","volume":"39","author":"Grundfest-Broniatowski","year":"1996","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijid.2024.107314_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fmed.2018.00096","article-title":"Novel antimicrobials for the treatment of Clostridium difficile infection","volume":"5","author":"Petrosillo","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijid.2024.107314_bib0006","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2024.107314_bib0007","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkaa289","article-title":"In vitro activity of eravacycline against common ribotypes of Clostridioides difficile","volume":"75","author":"Bass\u00e8res","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2024.107314_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0041-1740973","article-title":"Fulminant Clostridioides difficile infection: a review of treatment options for a life-threatening infection","volume":"43","author":"Carlson","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2024.107314_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00001-22","article-title":"Impact of tigecycline on C. difficile outcomes: case series and propensity-matched retrospective study","volume":"66","author":"Phillips","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2024.107314_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224003904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224003904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T20:38:58Z","timestamp":1741293538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224003904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":10,"alternative-id":["S1201971224003904"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107314","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of adjunctive eravacycline for severe and fulminant Clostridioides difficile infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107314"}}